BIO Patient and Health Advocacy Summit draws 325 attendees.

Press Release Summary:



Bringing together patient advocacy groups, health care provider organizations, academia, government, and biotechnology industry representatives, BIO Patient and Health Advocacy Summit provides forum for lively discussion, networking, and educational programming to advance partnerships among stakeholders and to share best practices. During Summit, Clinical Trials Transformation Initiative launched their recommendations for Effective Engagement with Patient Groups Around Clinical Trials.



Original Press Release:



2015 BIO Patient and Health Advocacy Summit Draws Record 325 Attendees



Recommendations Unveiled from CTTI’s Patient Groups & Clinical Trials Project



Opening Keynote Lunch Featured FDA CDER Director Dr. Janet Woodcock



WASHINGTON –The fourth annual BIO Patient and Health Advocacy Summit concluded today, bringing together patient advocacy groups, health care provider organizations, academia, government and biotechnology industry representatives. The event provides a forum for lively discussion, networking and educational programming to advance partnerships among stakeholders in the healthcare ecosystem and share best practices. Organized by the Biotechnology Industry Organization (BIO), the event drew a record-breaking 325 attendees.



“These recommendations provide specific, actionable steps for all stakeholders to take in pursuing meaningful collaborations throughout the continuum of drug development.”



“Facilitating partnerships with patient advocacy groups as well as all stakeholders is an increasingly critical component of the drug development ecosystem,” said Paul Hastings, Chairman and CEO of OncoMed Pharmaceuticals and Chair of BIO’s Patient Advocacy Committee. “The relationships formed and information shared at this year’s BIO Patient and Health Advocacy Summit will play a role for years to come in accelerating the development of new cures and treatments for patients in need. As a biotech CEO, I come away from this event each year with new knowledge and connections that will help my company incorporate the patient perspective into all of our drug development programs.”



Today at the Summit, the Clinical Trials Transformation Initiative (CTTI) launched their recommendations for Effective Engagement with Patient Groups Around Clinical Trials. The recommendations are the culmination of the Patient Groups & Clinical Trials (PGCT) Project, initiated by CTTI in January of 2014 to find evidence-based, actionable solutions for effective engagement between research sponsors, investigators and patient groups. A full copy of the recommendations may be downloaded here.



“The BIO Patient and Health Advocacy Summit provided an important venue for the unveiling of our recommendations, with the presence of so many patient and industry groups who are eager to collaborate,” said Bray Patrick-Lake, Director of Stakeholder Engagement for CTTI. “These recommendations provide specific, actionable steps for all stakeholders to take in pursuing meaningful collaborations throughout the continuum of drug development.”



The Summit’s opening luncheon featured keynote speaker Janet Woodcock, M.D., Director of the Center for Drug Evaluation and Research at the FDA. Dr. Woodcock’s remarks focused on efforts to ensure meaningful patient engagement throughout the drug development process and the critical role that patient input plays in enabling the FDA make informed regulatory decisions.



The full program and speaker lineup may be found here. Join and follow the conversation around the Summit on Twitter with #BIOSummit2015.



The BIO Patient and Health Advocacy Summit is possible thanks to the generous support of our sponsors, including Gold Sponsors: AstraZeneca, Celgene, Genentech, Eli Lilly and Shire; Silver Sponsors: Amgen and Astellas; and Bronze Sponsors: Alexion, Baxalta, Biogen, Horizon Pharma, Johnson & Johnson, Merck, Pfizer and Vertex.



About BIO

BIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIOtechNOW is BIO's blog chronicling “innovations transforming our world” and the BIO Newsletter is the organization’s bi-weekly email newsletter. Subscribe to the BIO Newsletter.



Upcoming BIO Events



BIO International Convention

June 6-9, 2016

San Francisco, Calif.



BIO Latin America Conference

October 14-16, 2015

Rio de Janeiro, Brazil



PMC/BIO Solutions Summit

October 14, 2015

Washington, D.C.



BIO Investor Forum

October 20-21, 2015

San Francisco, Calif.



BIO-Europe

November 2-4, 2015

Munich, Germany



BIO IP Counsels Committee Conference

November 16-18, 2015

Cary/Raleigh, NC



BIO CEO & Investor Conference

February 8-9, 2016

New York, New York



13th Annual BIO Asia International Conference

March 15-16, 2016

Tokyo, Japan



Contacts

Biotechnology Industry Organization (BIO)

Daniel Seaton

202-470-5207

Web: www.bio.org

Blog: www.biotech-now.org

Twitter: @IAmBiotech

All Topics